Leishmania donovani Triose Phosphate Isomerase: A Potential Vaccine Target against Visceral Leishmaniasis

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Kushawaha, Pramod K ^a   Gupta, Reema ^a   Tripathi, Chandra Dev Pati ^a   Khare, Prashant ^a   Jaiswal, Anil Kumar ^a   Sundar, Shyam ^b   Dube, Anuradha ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b BANARAS HINDU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DNA; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; LEISHMANIA VACCINE; NITRIC OXIDE; PARASITE ANTIGEN; RECOMBINANT PROTEIN; TRIOSEPHOSPHATE ISOMERASE VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DELAYED HYPERSENSITIVITY; DNA IMMUNIZATION; DOWN REGULATION; DRUG TARGETING; ENZYME PURIFICATION; FEMALE; HAMSTER; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; LEISHMANIA DONOVANI; LYMPHOCYTE PROLIFERATION; MALE; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; PROTEIN EXPRESSION; TH1 CELL; UPREGULATION; VACCINATION REACTION; VISCERAL LEISHMANIASIS;

ANIMALS; CELL LINE; CELL PROLIFERATION; CLONING, MOLECULAR; CRICETINAE; CYTOKINES; FEMALE; GLYCOLYSIS; HUMANS; IMMUNOGLOBULIN G; INTERFERON-ALPHA; INTERLEUKIN-12; INTERLEUKIN-4; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; MALE; MESOCRICETUS; NITRIC OXIDE; PROTEIN STRUCTURE, TERTIARY; RNA, MESSENGER; TRIOSE-PHOSPHATE ISOMERASE;

CRICETINAE; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; MESOCRICETUS AURATUS;

EID: 84866707206     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045766     Document Type: Article

References (71)

1. Alvar J, Yactayo S, Bern C, (2006) Leishmaniasis and poverty. Trends Parasitol 22: 552-557.
2. Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, et al. (2002) Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2: 494-501.
3. Desjeux P, (2004) Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27: 305-318.
4. Singh SP, Reddy DC, Rai M, Sundar S, (2006) Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India. Trop Med Int Health 11: 899-905.
5. Handman E, (2001) Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 14: 229-243.
6. Sinha PK, Pandey K, Bhattacharya SK, (2005) Diagnosis & management of leishmania/HIV co-infection. Indian J Med Res 121: 407-414.
7. Bacellar O, Brodskyn C, Guerreiro J, Barral-Netto M, Costa CH, et al. (1996) Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis. J Infect Dis 173: 1515-1518.
8. Modabber F, (1995) Vaccines against leishmaniasis. Ann Trop Med Parasitol 89Suppl 1: 83-88.
9. Evans KJ, Kedzierski L (2012) Development of Vaccines against Visceral Leishmaniasis. J Trop Med: 892817.
10. Herwaldt BL, (1999) Leishmaniasis. Lancet 354: 1191-1199.
11. Stanley AC, Engwerda CR, (2007) Balancing immunity and pathology in visceral leishmaniasis. Immunol Cell Biol 85: 138-147.
12. Peruhype-Magalhaes V, Martins-Filho OA, Prata A, Silva Lde A, Rabello A, et al. (2005) Immune response in human visceral leishmaniasis: analysis of the correlation between innate immunity cytokine profile and disease outcome. Scand J Immunol 62: 487-495.
13. Hailu A, Menon JN, Berhe N, Gedamu L, Hassard TH, et al. (2001) Distinct immunity in patients with visceral leishmaniasis from that in subclinically infected and drug-cured people: implications for the mechanism underlying drug cure. J Infect Dis 184: 112-115.
14. Kubar J, Fragaki K, (2005) Recombinant DNA-derived leishmania proteins: from the laboratory to the field. Lancet Infect Dis 5: 107-114.
15. Gupta SK, Sisodia BS, Sinha S, Hajela K, Naik S, et al. (2007) Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of Leishmania donovani promastigotes. Proteomics 7: 816-823.
16. Kumari S, Samant M, Khare P, Sundar S, Sinha S, et al. (2008) Induction of Th1-type cellular responses in cured/exposed Leishmania-infected patients and hamsters against polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa. Vaccine 26: 4813-4818.
17. Gomez-Puyou A, Saavedra-Lira E, Becker I, Zubillaga RA, Rojo-Dominguez A, et al. (1995) Using evolutionary changes to achieve species-specific inhibition of enzyme action-studies with triosephosphate isomerase. Chem Biol 2: 847-855.
18. Velanker SS, Ray SS, Gokhale RS, Suma S, Balaram H, et al. (1997) Triosephosphate isomerase from Plasmodium falciparum: the crystal structure provides insights into antimalarial drug design. Structure 5: 751-761.
19. Liu L, Benten WP, Wang L, Hao X, Li Q, et al. (2005) Modulation of Leishmania donovani infection and cell viability by testosterone in bone marrow-derived macrophages: signaling via surface binding sites. Steroids 70: 604-614.
20. Zhu Y, Si J, Ham DA, Yu C, He W, et al. (2002) The protective immunity produced in infected C57BL/6 mice of a DNA vaccine encoding Schistosoma japonicum Chinese strain triose-phosphate isomerase. Southeast Asian J Trop Med Public Health 33: 207-213.
21. Zhu Y, Si J, Harn DA, Yu C, Liang Y, et al. (2004) The protective immunity of a DNA vaccine encoding Schistosoma japonicum Chinese strain triose-phosphate isomerase in infected BALB/C mice. Southeast Asian J Trop Med Public Health 35: 518-522.
22. Melby PC, Tryon VV, Chandrasekar B, Freeman GL, (1998) Cloning of Syrian hamster (Mesocricetus auratus) cytokine cDNAs and analysis of cytokine mRNA expression in experimental visceral leishmaniasis. Infect Immun 66: 2135-2142.
23. Garg R, Srivastava JK, Pal A, Naik S, Dube A, (2005) Isolation of integral membrane proteins of Leishmania promastigotes and evaluation of their prophylactic potential in hamsters against experimental visceral leishmaniasis. Vaccine 23: 1189-1196.
24. Garg R, Gupta SK, Tripathi P, Naik S, Sundar S, et al. (2005) Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani. Clin Exp Immunol 140: 149-156.
25. Dube A, Singh N, Sundar S, (2005) Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol Res 96: 216-223.
26. Dube A, Singh N, Sundar S, Singh N, (2005) Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol Res 96: 216-223.
27. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ, (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
28. Towbin H, Staehelin T, Gordon J, (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 76: 4350-4354.
29. Garg R, Gupta SK, Tripathi P, Hajela K, Sundar S, et al. (2006) Leishmania donovani: identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis. Vaccine 24: 2900-2909.
30. Bhowmick S, Ravindran R, Ali N, (2007) Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response. Vaccine 25: 6544-6556.
31. Kushawaha PK, Gupta R, Sundar S, Sahasrabuddhe AA, Dube A, (2011) Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-gamma and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge. J Immunol 187: 6417-6427.
32. Ding AH, Nathan CF, Stuehr DJ, (1988) Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 141: 2407-2412.
33. Samant M, Gupta R, Kumari S, Misra P, Khare P, et al. (2009) Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-Type immunoprotective response against experimental visceral leishmaniasis. J Immunol 183: 470-479.
34. Seder RA, Gazzinelli R, Sher A, Paul WE, (1993) Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci U S A 90: 10188-10192.
35. Reiner SL, Zheng S, Wang ZE, Stowring L, Locksley RM, (1994) Leishmania promastigotes evade interleukin 12 (IL-12) induction by macrophages and stimulate a broad range of cytokines from CD4+ T cells during initiation of infection. J Exp Med 179: 447-456.
36. Murray HW, (1983) How protozoa evade intracellular killing. Ann Intern Med 98: 1016-1018.
37. Vouldoukis I, Becherel PA, Riveros-Moreno V, Arock M, da Silva O, et al. (1997) Interleukin-10 and interleukin-4 inhibit intracellular killing of Leishmania infantum and Leishmania major by human macrophages by decreasing nitric oxide generation. Eur J Immunol 27: 860-865.
38. Murray HW, Nathan CF, (1999) Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J Exp Med 189: 741-746.
39. Bhowmick S, Ravindran R, Ali N, (2008) gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Infect Immun 76: 1003-1015.
40. Das A, Ali N, (2012) Vaccine Development Against Leishmania donovani. Front Immunol 3: 99.
41. Basu R, Bhaumik S, Basu JM, Naskar K, De T, et al. (2005) Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and-resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 174: 7160-7171.
42. Stager S, Smith DF, Kaye PM, (2000) Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol 165: 7064-7071.
43. Ghosh A, Zhang WW, Matlashewski G, (2001) Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 20: 59-66.
44. Tewary P, Jain M, Sahani MH, Saxena S, Madhubala R, (2005) A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis. J Infect Dis 191: 2130-2137.
45. Rafati S, Zahedifard F, Nazgouee F, (2006) Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 24: 2169-2175.
46. Wang Y, Chen Y, Xin L, Beverley SM, Carlsen ED, et al. (2011) Differential microbicidal effects of human histone proteins H2A and H2B on Leishmania promastigotes and amastigotes. Infect Immun 79: 1124-1133.
47. Melby PC, Yang J, Zhao W, Perez LE, Cheng J, (2001) Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immun 69: 4719-4725.
48. Aguilar-Be I, da Silva Zardo R, Paraguai de Souza E, Borja-Cabrera GP, Rosado-Vallado M, et al. (2005) Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect Immun 73: 812-819.
49. Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG (2007) Leish-111f, a Recombinant Polyprotein Vaccine that Protects against Visceral Leishmaniasis by the elicitation of CD4+ T cells. Infect Immun.
50. Velez ID, Gilchrist K, Martinez S, Ramirez-Pineda JR, Ashman JA, et al. (2009) Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine 28: 329-337.
51. Chakravarty J, Kumar S, Trivedi S, Rai VK, Singh A, et al. (2011) A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine 29: 3531-3537.
52. Kumari S, Samant M, Misra P, Khare P, Sisodia B, et al. (2008) Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1kDa offers long-lasting protection against experimental visceral leishmaniasis. Vaccine.
53. Liew FY, Li Y, Moss D, Parkinson C, Rogers MV, et al. (1991) Resistance to Leishmania major infection correlates with the induction of nitric oxide synthase in murine macrophages. Eur J Immunol 21: 3009-3014.
54. Assreuy J, Cunha FQ, Epperlein M, Noronha-Dutra A, O'Donnell CA, et al. (1994) Production of nitric oxide and superoxide by activated macrophages and killing of Leishmania major. Eur J Immunol 24: 672-676.
55. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA, (1997) DNA vaccines. Annu Rev Immunol 15: 617-648.
56. Maecker B, von B-B, Anderson KS, Vonderheide RH, Schultze JL, (2001) Linking genomics to immunotherapy by reverse immunology-'immunomics' in the new millennium. Curr Mol Med 1: 609-619.
57. Shedlock DJ, Weiner DB, (2000) DNA vaccination: antigen presentation and the induction of immunity. J Leukoc Biol 68: 793-806.
58. Melby PC, Chandrasekar B, Zhao W, Coe JE, (2001) The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J Immunol 166: 1912-1920.
59. Ali N, Afrin F, (1997) Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes. J Parasitol 83: 70-75.
60. Afrin F, Rajesh R, Anam K, Gopinath M, Pal S, et al. (2002) Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice. Infect Immun 70: 6697-6706.
61. Armijos RX, Weigel MM, Calvopina M, Hidalgo A, Cevallos W, et al. (2004) Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. Vaccine 22: 1320-1326.
62. Howard JG, Liew FY, (1984) Mechanisms of acquired immunity in leishmaniasis. Philos Trans R Soc Lond B Biol Sci 307: 87-98.
63. Ghose AC, Haldar JP, Pal SC, Mishra BP, Mishra KK, (1980) Serological investigations on Indian kala-azar. Clin Exp Immunol 40: 318-326.
64. Liew FY, Li Y, Millott S, (1990) Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol 145: 4306-4310.
65. Liew FY, Li Y, Millott S, (1990) Tumour necrosis factor (TNF-alpha) in leishmaniasis. II. TNF-alpha-induced macrophage leishmanicidal activity is mediated by nitric oxide from L-arginine. Immunology 71: 556-559.
66. Caldas A, Favali C, Aquino D, Vinhas V, van Weyenbergh J, et al. (2005) Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesis. BMC Infect Dis 5: 113.
67. Sundar S, Reed SG, Sharma S, Mehrotra A, Murray HW, (1997) Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am J Trop Med Hyg 56: 522-525.
68. Stern AS, Podlaski FJ, Hulmes JD, Pan YC, Quinn PM, et al. (1990) Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci U S A 87: 6808-6812.
69. Scharton-Kersten T, Afonso LC, Wysocka M, Trinchieri G, Scott P, (1995) IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J Immunol 154: 5320-5330.
70. Trinchieri G, (1993) Interleukin-12 and its role in the generation of TH1 cells. Immunol Today 14: 335-338.
71. Nylen S, Akuffo H, (2009) Tracing immunity to human leishmaniasis. Future Microbiol 4: 241-254.